Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Hematologic Neoplasms 1Anemia 1

Interventions

Magnetic Resonance Spectroscopy 284Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 224Nivolumab 182Cisplatin 172Biopsy 163Carboplatin 152Radiosurgery 139fludarabine 128Blood Specimen Collection 128Surveys and Questionnaires 117Gemcitabine 117Paclitaxel 114Standard of Care 110venetoclax 109Dexamethasone 103Bevacizumab 96Radiation 92Rituximab 89Oxaliplatin 86Capecitabine 86Cytarabine 85Drug Therapy 83Ipilimumab 81Doxorubicin 81durvalumab 80atezolizumab 74fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × luspatercept × 90 days × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
196 enrolled
MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡